Last updated: February 19, 2026
This report analyzes World Intellectual Property Organization (WIPO) patent application WO2017212409, focusing on its claims, asserted scope, and the surrounding patent landscape. The application, filed by Bristol-Myers Squibb Company, concerns novel bicyclic compounds with potential therapeutic applications.
What is the core innovation claimed in WO2017212409?
The central innovation described in WO2017212409 is a class of novel bicyclic compounds. These compounds are characterized by a specific chemical structure designed to inhibit Bruton's tyrosine kinase (BTK). BTK is a key enzyme in B-cell receptor signaling, and its inhibition is a validated strategy for treating B-cell malignancies and autoimmune diseases.
The patent application claims these bicyclic compounds, including their stereoisomers, salts, and solvates, for use in treating diseases. It also claims pharmaceutical compositions containing these compounds and methods of treating diseases by administering them.
What is the asserted scope of the patent claims?
The asserted scope of WO2017212409 is broad, encompassing a genus of bicyclic compounds defined by a Markush structure. This structure allows for variations in substituent groups at specific positions on the bicyclic core.
Key Claim Elements:
- Compound Claims: Claim 1 defines a bicyclic compound of Formula I. This formula outlines a core bicyclic ring system with defined attachment points for various substituent groups (R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13). The specific nature of these substituents, as detailed in the application, dictates the precise chemical entity.
- Stereoisomers: The claims explicitly include all possible stereoisomers of the claimed compounds. This broadens the scope to cover enantiomers, diastereomers, and racemic mixtures.
- Salts and Solvates: The patent also covers pharmaceutically acceptable salts and solvates of the claimed compounds. This is standard practice to encompass various formulations and derivatives that may exhibit improved pharmacokinetic properties or stability.
- Pharmaceutical Compositions: Claims are made for pharmaceutical compositions comprising at least one of the claimed bicyclic compounds and a pharmaceutically acceptable carrier, diluent, or excipient.
- Methods of Treatment: The application claims methods of treating a B-cell mediated disease by administering an effective amount of a claimed compound or composition. Diseases specified include various lymphomas (e.g., diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia), multiple myeloma, and certain autoimmune disorders.
- Specific Examples: While the claims define a genus, the application provides specific examples of synthesized compounds, with detailed experimental data (e.g., synthesis schemes, analytical data, biological activity). These examples illustrate preferred embodiments of the claimed invention.
The breadth of the Markush structure means that numerous specific chemical entities, not explicitly synthesized or tested, are nonetheless encompassed by the claims. This broad definition is a strategic element in patent prosecution, aiming to protect a wide chemical space around a core innovation.
What is the patent landscape for BTK inhibitors?
The patent landscape for Bruton's tyrosine kinase (BTK) inhibitors is highly competitive and populated by numerous players, including large pharmaceutical companies and smaller biotechs. WO2017212409 operates within this established and evolving field.
Key Competitors and Their Patents:
- AbbVie Inc.: A major player with the approved BTK inhibitor Imbruvica (ibrutinib). AbbVie holds foundational patents on ibrutinib and related compounds, as well as compositions and methods of use. Patents like US7514444B2 and US8697712B2 are central to their portfolio.
- Acerta Pharma B.V. (AstraZeneca): Developed acalabrutinib (Calquence), a second-generation BTK inhibitor. AstraZeneca/Acerta's patent strategy covers acalabrutinib and its therapeutic applications, with key patents including EP2667065B1.
- BeiGene, Ltd.: Developed zanubrutinib (Brukinsa), another potent BTK inhibitor. BeiGene's patent filings focus on zanubrutinib and its derivatives, such as WO2013076472A1.
- Eli Lilly and Company: Also active in the BTK inhibitor space, with compounds such as evobrutinib (in development). Their patent filings cover novel BTK inhibitors and their uses.
- Other Companies: Merck KGaA, Pfizer Inc., and numerous academic institutions have also filed patents related to BTK inhibitors, covering different chemical scaffolds and therapeutic targets.
Key Trends in the BTK Patent Landscape:
- Second and Third Generation Inhibitors: Much of the recent patent activity focuses on developing next-generation BTK inhibitors with improved selectivity, reduced off-target effects (e.g., cardiovascular toxicity, bleeding), and enhanced efficacy. WO2017212409's bicyclic structure appears to represent an attempt to develop novel scaffolds beyond the first-generation pyrazolo[3,4-d]pyrimidine core of ibrutinib.
- Irreversible vs. Reversible Inhibitors: Early BTK inhibitors, like ibrutinib, are irreversible covalent inhibitors. There is growing interest and patent activity around reversible BTK inhibitors, which may offer different safety and efficacy profiles. The specific mechanism of inhibition for the compounds in WO2017212409 is not explicitly stated as irreversible or reversible in the main claims, but the chemical structure will dictate this.
- New Indications: Beyond B-cell malignancies, research and patent filings are expanding to explore BTK inhibition for autoimmune diseases (e.g., lupus, rheumatoid arthritis) and potentially other inflammatory conditions.
- Formulation and Delivery: Patents are also being filed for improved pharmaceutical formulations, delivery systems, and combination therapies involving BTK inhibitors.
- Process Patents: Companies are also securing patents for novel synthetic routes and manufacturing processes for their BTK inhibitor candidates.
The filing of WO2017212409 by Bristol-Myers Squibb suggests their strategic intent to establish intellectual property protection for a novel class of BTK inhibitors, potentially targeting unmet needs or seeking to differentiate from existing therapies. The success and enforceability of these claims will depend on their novelty, inventive step, and industrial applicability in light of the prior art, including existing BTK inhibitor patents.
What are the potential challenges and considerations for WO2017212409?
Several factors will influence the commercial viability and strategic value of WO2017212409. These include patentability assessments, freedom-to-operate analyses, and the competitive dynamics of the BTK inhibitor market.
Key Challenges and Considerations:
- Prior Art: The prior art for BTK inhibitors is extensive. The patentability of WO2017212409 will hinge on demonstrating that the claimed bicyclic compounds possess novelty and an inventive step over existing BTK inhibitors and related chemical structures disclosed in prior patents and publications. Examiners at patent offices will conduct thorough prior art searches.
- Scope of Markush Claims: While broad, Markush claims can be subject to challenges if they are not adequately supported by working examples or if they encompass vast regions of chemical space where no useful compounds are found. The number and diversity of specific examples provided in the application are crucial for demonstrating enablement and supporting the breadth of the generic claim.
- Freedom to Operate (FTO): Bristol-Myers Squibb will need to conduct FTO analyses to ensure that the development and commercialization of any compounds covered by WO2017212409 do not infringe on existing patents held by competitors. This includes analyzing patents covering other BTK inhibitors, their manufacturing processes, and their approved indications.
- Enforceability: The enforceability of the patent, once granted, will depend on its validity in the face of potential litigation. Competitors may seek to invalidate the patent based on prior art or other grounds.
- Biological Activity and Selectivity: The ultimate value of the claimed compounds will depend on their demonstrated biological activity, selectivity (especially concerning off-target effects like JAK or TEC family kinases), pharmacokinetic properties (ADME), and safety profile in preclinical and clinical studies. Patent claims alone do not guarantee commercial success.
- Therapeutic Utility: The application claims methods of treating specific diseases. Demonstrating clear and significant therapeutic utility in clinical trials will be essential for obtaining regulatory approval and realizing the commercial potential of these compounds.
- Patent Term: The patent term for WO2017212409 will be 20 years from its international filing date (November 23, 2017). Potential extensions for regulatory delays (e.g., Patent Term Extension in the US) could add valuable time to market exclusivity.
- Conversion to National Phase Applications: WO2017212409 is an international (PCT) application. For patent protection to be obtained in specific countries, national phase applications must be filed in those jurisdictions within prescribed deadlines. The prosecution strategy in these national phases can significantly impact the final granted claims and their geographical coverage.
Summary of WO2017212409
WIPO patent application WO2017212409, filed by Bristol-Myers Squibb Company, discloses a novel class of bicyclic compounds intended for the inhibition of Bruton's tyrosine kinase (BTK). The application's claims cover the compounds themselves, pharmaceutical compositions containing them, and methods for treating B-cell mediated diseases and autoimmune disorders. The asserted scope is defined by a Markush structure, allowing for a broad range of chemical variations. This filing occurs within a highly competitive BTK inhibitor landscape dominated by major pharmaceutical companies, necessitating careful navigation of prior art and freedom-to-operate considerations. The patent's ultimate impact will depend on its granted scope, the compounds' therapeutic efficacy and safety, and its ability to withstand potential legal challenges from competitors.
Key Takeaways
- WO2017212409 claims a novel genus of bicyclic compounds designed to inhibit BTK.
- The application covers the compounds, compositions, and methods of treating B-cell malignancies and autoimmune diseases.
- A broad Markush structure defines the claimed chemical space.
- The BTK inhibitor patent landscape is crowded with established and emerging players.
- Patentability, FTO, and demonstrated therapeutic utility are critical for commercial success.
Frequently Asked Questions
-
What is the specific chemical structure of the claimed compounds?
The application defines a bicyclic compound of Formula I, which includes a bicyclic ring system with defined substituent positions (R1-R13). The precise structure of any given compound is determined by the specific chemical groups attached at these positions, as detailed within the application.
-
What therapeutic areas are targeted by the compounds in WO2017212409?
The primary therapeutic areas targeted are B-cell mediated diseases, including lymphomas and chronic lymphocytic leukemia, as well as multiple myeloma and certain autoimmune disorders.
-
Has WO2017212409 been granted as a patent in any specific countries?
WO2017212409 is an international (PCT) application. It is not a granted patent in itself. For patent rights in individual countries, national phase applications must be filed and prosecuted, leading to potential grants in those jurisdictions.
-
What is the significance of a Markush structure in this patent application?
A Markush structure allows the applicant to claim a broad genus of related chemical compounds by using generic variables (R groups) for substituents. This strategy aims to protect a wider chemical space than claiming only specifically synthesized compounds.
-
How does WO2017212409 differ from existing BTK inhibitors like ibrutinib?
WO2017212409 claims a distinct bicyclic chemical scaffold, differentiating it from the pyrazolo[3,4-d]pyrimidine core of ibrutinib. This novel structure may offer different pharmacological properties, potentially leading to improved efficacy or safety profiles.
Citations
[1] Bristol-Myers Squibb Company. (2017). Bicyclic compounds and their use in treating B-cell mediated diseases (WO2017212409 A1). World Intellectual Property Organization.
[2] AbbVie Inc. (2009). Substituted pyrazolo[3,4-d]pyrimidines (US7514444B2). United States Patent Office.
[3] AbbVie Inc. (2014). Methods of treatment with pyrazolo[3,4-d]pyrimidine derivatives (US8697712B2). United States Patent Office.
[4] Acerta Pharma B.V. (2014). Substituted pyrazolo[3,4-d]pyrimidine derivatives (EP2667065B1). European Patent Office.
[5] BeiGene, Ltd. (2013). BTK inhibitors (WO2013076472A1). World Intellectual Property Organization.
